Amaxa Biosystems

[b]Amaxa Biosystems was acquired by Lonza Group[/b]    Amaxa Biosystems GmbH develops and commercializes gene transfer technologies and products. The company offers Nucleofector Technology, a transfection solution which enables the transfer of various substrates, such as DNA, RNA, or peptides into cells. It also offers transfection services; HiFect transfection reagent, the transfection reagent for standard cell lines; antibiotics for the treatment and prevention of mycoplasma and other microbial contaminants; Expression Vectors for the expression of bright fluorescent proteins and individual customer constructs in mammalian cells; and peptide Nucleofection and transfection control solutions. Amaxa Biosystems offers its solutions in Canada, China, Croatia, Greece, Hong Kong, Indonesia, Japan, Korea, Malaysia, Mexico, Portugal, Singapore, Spain, Taiwan, and Turkey. The company was founded in 1998 and is based in Cologne, Germany. As of July 2, 2008, Amaxa Biosystems GmbH operates as a subsidiary of Lonza Group AG.